Stage IIIA/B NSCLC: rationale for multimodal diversity

Wilfried Ernst Erich Eberhardt (Essen, Germany)

Source: International Congress 2017 – Rational strategies for specific treatment situations in lung cancer
Session: Rational strategies for specific treatment situations in lung cancer
Session type: Symposium
Number: 263

WebcastSlide presentation

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Wilfried Ernst Erich Eberhardt (Essen, Germany). Stage IIIA/B NSCLC: rationale for multimodal diversity. International Congress 2017 – Rational strategies for specific treatment situations in lung cancer

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery
Source: ISSN=ISSN 1810-6838, ISBN=, page=279
Year: 2008

Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery
Source: Eur Respir J 2001; 18: Suppl. 33, 318s
Year: 2001

Phase II study of cisplatin-vinorelbine sequenced by gemcitabine-vinorelbine in patients with unresectable non-small-cell lung cancer (NSCLC): preliminary results
Source: Eur Respir J 2003; 22: Suppl. 45, 30s
Year: 2003

Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
Source: Eur Respir J 2013; 42: 1119-1133
Year: 2013



Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

New treatment concepts in stage IV non-small cell lung cancer: personalised multidisciplinary approaches
Source: Virtual Congress 2021 – Thoracic oncology
Year: 2021


Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


Interdisciplinary multimodality management of stage III nonsmall cell lung cancer
Source: Eur Respir Rev, 28 (152) 190024; 10.1183/16000617.0024-2019
Year: 2019



Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008


Modern radiotherapy as a curative treatment modality for stage III NSCLC
Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease
Year: 2019


Treatment of unresectable locoregional (stage III) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005


Chemotherapy plus resection is not better than chemoradiotherapy for baseline unresectable stage IIIA-N2 NSCLC
Source: ISSN=ISSN 1810-6838, ISBN=, page=380
Year: 2007

Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up
Source: Eur Respir J 2006; 28: Suppl. 50, 772s
Year: 2006